Ms. Slack has 30+ years of extensive leadership and management experience in both the public and private sectors, developing informatics strategy and implementing business solutions. She currently serves as Director of FDA’s CDER Office of Strategic Programs (OSP). OSP plays a lead role in many of the Center’s and FDA’s strategic initiatives, including decision support, data standards, program analysis, informatics and governance. Since joining CDER in 2003, Ms. Slack has led numerous large, complex initiatives with broad stakeholder impact, including establishing CDER’s data standards program and leading a team of experts in defining FDA’s operational implementation of the FDA-EU mutual recognition of inspections. Ms. Slack serves on several Boards and Committees where she supports FDA’s needs and perspectives.
- Amy P. Abernethy, US FDA
- Graeme Archer, GSK R&D
- Jesse Berlin, Johnson & Johnson
- Lawrence Carin, Duke
- Noémie Elhadad, Columbia
- Igor Jurisica, Krembil Research Institute and University of Toronto
- Faisal Khan, AstraZeneca
- Kannan Natarajan, Pfizer
- Amol Navathe, University of Pennsylvania
- Adler Perotte, Columbia
- Patrick Ryan, Janssen Research and Development
- Mary Ann Slack, US Food and Drug Administration (FDA)
- Simon Tavaré, Columbia
- Mihaela van der Schaar, Cambridge
- Li Wang, AbbVie
Countdown to AIPM
AIPM has begun!
Welcome Address — David Madigan, Ph.D., Columbia University
A Perspective on the Promise and Pitfalls of Artificial Intelligence in Clinical Drug Development — Kannan Natarajan, Pfizer Inc.
Machine Learning: Changing the future of healthcare – from next generation clinical trials to individualized treatment effects — Mihaela van der Schaar, University of Cambridge
Discussant — Patrick Ryan, Janssen Research and Development
ML and AI in Clinical Development and Statistical Innovation — Wang Li, AbbVie.
Opportunities for AI in Healthcare — Lawrence Carin, Duke University
- Demissie Alemayehu, Pfizer Inc.
- David Madigan, Columbia University